Preclinical studies suggest that TKR inhibitors targeting PDGFR, VEGFR, and FGFR are able to inhibit the growth of CS in animal models due to their antiangiogenic effects [65]. This evidence concerns the gene PDGFRB and Cowden syndrome 1.